New combo therapy shows promise for tough head and neck cancers
NCT ID NCT00939627
First seen Mar 17, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This phase 2 trial tested whether adding sorafenib to the standard drug cetuximab works better than cetuximab alone for people with advanced head and neck cancer that has come back or spread. Fifty-five patients were randomly assigned to one of the two treatments. The main goal was to see how long patients lived without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TONGUE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Billings Clinic
Billings, Montana, 59107-7000, United States
-
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Montefiore Medical Center
The Bronx, New York, 10467-2490, United States
-
Suburban Hospital
Bethesda, Maryland, 20814, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cetuximab and sorafenib tosylate
What this could lead to
If successful, this could point toward a new combination treatment option for patients with advanced head and neck cancer that has not responded to prior therapies.
What could go wrong
This is a small, early-phase trial with only 55 participants. The combination may not improve survival or could cause added side effects like fatigue, rash, or high blood pressure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.